• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Transthyretin amyloid cardiomyopathy (ATTR-CM) results in a restrictive cardiomyopathy
caused by extracellular deposition of transthyretin, normally involved in the transportation of …

Background Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with
accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive …

Background Transthyretin amyloid cardiomyopathy is characterized by the deposition of
misfolded monomeric transthyretin (TTR) in the heart. Acoramidis is a high-affinity TTR …

Background Transthyretin amyloid (ATTR) cardiomyopathy is a progressive and fatal
disease caused by misfolded transthyretin. Despite advances in slowing disease …

BACKGROUND: Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a
progressive, fatal disease. Vutrisiran, a subcutaneously administered RNA interference …

The systemic amyloidoses are a broad spectrum of diseases that result from misfolding of
proteins that aggregate into b-sheet amyloid fibrils. Over 35 amyloidogenic precursor …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …

Transthyretin amyloid cardiomyopathy (ATTR-CM) is an under-recognized cause of heart
failure (HF) in older adults, resulting from myocardial deposition of misfolded transthyretin …